吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

休市中 06-12 16:00:00 EDT

125.59

-0.28

-0.22%

盘后125.75

+0.16+0.13%

19:59 EDT

最高126.51	最低124.29	成交量521.61万
今开126.13	昨收125.87	日振幅1.76%
总市值1,558亿	流通市值1,555亿	总股本12.41亿
成交额6.53亿	换手率0.42%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":125.59,"timestamp":1781294400000,"preClose":125.87,"halted":0,"volume":5216092,"hourTrading":{"tag":"盘后","latestPrice":125.75,"preClose":125.59,"latestTime":"19:59 EDT","volume":146105,"amount":18350054.5936,"timestamp":1781308772576,"change":0.16,"changeRate":0.001274,"amplitude":0.003424},"delay":0,"changeRate":-0.0022245173591801154,"floatShares":1238162880,"shares":1240679623,"eps":7.352725,"marketStatus":"休市中","change":-0.28,"latestTime":"06-12 16:00:00 EDT","open":126.13,"high":126.505,"low":124.29,"amount":653425718.159592,"amplitude":0.017598,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.352725,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":125.87,"dividendRate":0.0254,"preHourTrading":{"tag":"盘前","latestPrice":125.91,"preClose":125.87,"latestTime":"09:29 EDT","volume":1059,"amount":133755.23706,"timestamp":1781270999999,"change":0.04,"changeRate":0.000318,"amplitude":0.011631},"postHourTrading":{"tag":"盘后","latestPrice":125.75,"preClose":125.59,"latestTime":"19:59 EDT","volume":146105,"amount":18350054.5936,"timestamp":1781308772576,"change":0.16,"changeRate":0.001274,"amplitude":0.003424},"volumeRatio":0.495183993390988,"impliedVol":0.2749,"impliedVolPercentile":0.1873},"requestUrl":"/m/hq/s/GILD/tweets","defaultTab":"tweets","newsList":[{"id":"1171165703","title":"异动解读｜吉利德科学盘中上涨3.52%，HIV新药积极数据助力股价超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1171165703","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171165703?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:58","pubTimestamp":1781186338,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中上涨3.52%，报125.095美元/股，成交额1.01亿美元。此前该股因Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期研究被终止而连续承压，累计跌幅显著。消息面上，吉利德科学与默沙东此前公布的HIV药物Islatravir/Lenacapavir口服每周一次治疗方案两项三期试验均达到第48周主要疗效终点，且不劣于必妥维和标准抗逆转录病毒疗法，两家公司计划向全球监管机构提交申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194875002","title":"国家艾滋病纪念园与吉利德基金会启动重大投资，扩展艾滋病教育与社区领导力","url":"https://stock-news.laohu8.com/highlight/detail?id=1194875002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194875002?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:34","pubTimestamp":1781181267,"startTime":"0","endTime":"0","summary":"国家艾滋病纪念园与吉利德基金会宣布，将启动一项重大投资项目，旨在显著扩展艾滋病相关的教育项目并加强社区的领导能力建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1023059063.AUD","SG9999015986.USD","IE00BKVL7J92.USD","LU0965509010.AUD","LU2089984988.USD","SG9999015978.USD","LU1037948897.HKD","LU2324357040.USD","LU1934455277.USD","IE00B7SZLL34.SGD","LU1061106388.HKD","LU0965509283.SGD","LU1674673691.USD","IE00B19Z3B42.SGD","LU1674673428.USD","BK4588","LU1066053197.SGD","BK4566","LU1778281490.HKD","LU0882574055.USD","BK4532","BK4585","BK4550","LU0320765992.SGD","LU1934455863.HKD","BK4578","IE00B19Z3581.USD","LU0861579265.USD","LU1839511570.USD","LU0234570918.USD","LU2087621335.USD","LU0289739699.SGD","LU1037948541.HKD","IE00BSNM7G36.USD","LU0058720904.USD","LU1066051498.USD","LU2112291526.USD","BK4583","LU1057294990.SGD","LU0109394709.USD","BK4568","LU0122379950.USD","BK4139","LU0965509101.SGD","LU0823416689.USD","LU1430594728.SGD","LU0114720955.EUR","LU2468319806.SGD","LU0965508806.USD","LU1585245621.USD","IE0002270589.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","SG9999015945.SGD","IE00B3T34201.USD","GILD","SG9999015952.SGD","LU1934455194.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167309488","title":"异动解读｜吉利德科学盘中下跌3.06%，Trodelvy肺癌三期试验终止持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167309488","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167309488?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:36","pubTimestamp":1781113006,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中下跌3.06%，报121.66美元/股，成交额5.19亿美元。消息面上，吉利德科学与默沙东此前宣布，基于数据监测委员会建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy作为吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。此外，加拿大皇家银行指出体内CAR-T早期技术可能威胁吉利德未来10%至15%的收入，进一步加剧市场担忧。同期公布的HIV药物Islatravir/Lenacapavir三期积极数据未能有效对冲肿瘤管线利空。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119573472","title":"异动解读｜吉利德科学盘中下跌3.29%，Trodelvy联合Keytruda肺癌三期试验宣布终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1119573472","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119573472?lang=zh_cn&edition=full","pubTime":"2026-06-09 22:07","pubTimestamp":1781014061,"startTime":"0","endTime":"0","summary":"6月9日，吉利德科学盘中下跌3.29%，报123.73美元/股，成交额1.6亿美元。消息面上，吉利德科学与默沙东宣布，基于数据监测委员会的建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy是吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。同日公布的HIV药物Islatravir/Lenacapavir三期积极数据未能对冲肿瘤管线利空。吉利德科学公司是一家以研究为基础的生物制药公司，主要聚焦病毒性疾病、炎性和纤维化疾病以及肿瘤学领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642545787","title":"默沙东(MRK.US)与吉利德科学(GILD.US)联合HIV药物三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642545787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642545787?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:47","pubTimestamp":1780987633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，默沙东和吉利德科学表示，含有默沙东药物伊斯拉曲韦和吉利德药物莱那卡帕韦的复方药片的两项 3 期试验的初步结果达到了主要终点。此外，研究发现 islatravir/lenacapavir不劣于必妥维和标准口服抗逆转录病毒疗法。此外，两家公司宣布，根据数据监测委员会的建议，他们将终止吉利德的 Trodelvy 与默沙东的Keytruda一线治疗转移性非小细胞肺癌的 3 期 KEYNOTE-D46/EVOKE-03 研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1201861249.SGD","IE00BZ1G4Q59.USD","IE0009355771.USD","LU1585245621.USD","BK4533","SG9999014542.SGD","LU1066053197.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","BK4566","LU1066051811.HKD","SG9999014567.USD","BK4532","IE00B4R5TH58.HKD","SG9999002224.SGD","LU1674673691.USD","SG9999015952.SGD","LU0965509101.SGD","LU2023250843.SGD","LU2125154778.USD","LU0122379950.USD","LU0965508806.USD","LU0006306889.USD","SG9999015341.SGD","BK4007","IE00B1BXHZ80.USD","IE00B7SZLL34.SGD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU0320765992.SGD","LU2125154935.USD","LU2491050154.USD","LU0965509010.AUD","LU2491049909.HKD","LU0868494617.USD","SG9999014575.USD","LU0859254822.USD","BK4534","LU1929549753.HKD","LU2125909247.SGD","LU0114720955.EUR","LU1116320901.HKD","IE00BBT3K403.USD","LU1917777945.USD","LU0211331839.USD","IE00BSNM7G36.USD","LU0238689110.USD","LU0320765489.SGD","LU2361045086.USD","SG9999015945.SGD","IE00BN8TJ469.HKD","LU2125909593.SGD","LU0130517989.USD","LU0234570918.USD","LU1061106388.HKD","LU0882574055.USD","LU0942090050.USD","SGXZ57979304.SGD","LU1941712264.USD","SG9999015978.USD","GILD","BK4568","LU0648001328.SGD","LU0823416689.USD","LU2106854487.HKD","BK4559","LU1093756168.USD","LU1066051225.USD","BK4550","LU1057294990.SGD","LU1839511570.USD","LU2112291526.USD","LU2324357040.USD","LU1069347547.HKD","LU2360032135.SGD","LU0098860793.USD","LU0477156953.USD","LU1674673428.USD","BK4583","LU1066051498.USD","LU1699723380.USD","LU0965509283.SGD","LU1923622614.USD","LU2089984988.USD","SG9999002232.USD","LU1941712348.USD","LU0980610538.SGD","LU1934455277.USD","LU2087621335.USD","LU2357627491.SGD","LU0234572021.USD","LU1093756325.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","BK4139","BK4578","LU2023250504.SGD","IE00B19Z3581.USD","LU0432979614.USD","LU0861579265.USD","LU1989771016.USD","IE000M9KFDE8.USD","LU1934455194.USD","LU2361044865.SGD","LU1989772840.SGD","IE00BLSP4239.USD","SG9999014559.SGD","LU1037948541.HKD","LU0106261372.USD","BK4588","IE00BKVL7J92.USD","LU0130102774.USD","IE00B3T34201.USD","SG9999001176.SGD","LU1934455863.HKD","LU0868494708.USD","IE0002270589.USD","LU2468319806.SGD","BK4585","LU1430594728.SGD","LU0889565916.HKD","SG9999015358.SGD","LU1989772923.USD","IE00B2B36J28.USD","LU0320765646.SGD","IE0002141913.USD","LU0109394709.USD","LU0208291251.USD","LU0070302665.USD","LU0265550359.USD","LU1291159041.SGD","LU1116320737.USD","LU1571399168.USD","LU0203347892.USD","LU2491050071.SGD","LU1037948897.HKD","LU0266013472.USD","SG9999001440.SGD","LU1023059063.AUD","SG9999001176.USD","MRK","LU1778281490.HKD","LU0203345920.USD","SG9999013999.USD","LU2433249047.HKD","SG9999015986.USD","LU1162221912.USD","LU0289739699.SGD","LU1035773651.USD","LU1974910355.USD","LU0058720904.USD","LU0985320562.USD","BK4516","LU2461242641.AUD","LU2361044949.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181239601","title":"吉利德科学：Islatravir/Lenacapavir HIV治疗方案在两项试验中均达到第48周主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1181239601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181239601?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951065,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，其基于islatravir与lenacapavir的HIV联合治疗方案，在两项关键临床试验中，均成功达到了预设的第48周主要疗效终点。这一积极结果标志着该创新疗法在抑制病毒载量方面展现出显著效果，为HIV感染者提供了潜在的全新长效治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU1291159041.SGD","LU1571399168.USD","LU1023059063.AUD","BK4550","SG9999014567.USD","SG9999014559.SGD","BK4516","IE00BKVL7J92.USD","BK4534","LU2324357040.USD","IE00B19Z3B42.SGD","LU1941712348.USD","LU2023250843.SGD","LU1839511570.USD","SG9999002232.USD","LU0098860793.USD","IE00BLSP4452.SGD","BK4533","LU2125909593.SGD","LU2357627491.SGD","SG9999015986.USD","LU2361044949.HKD","LU0868494617.USD","LU0882574055.USD","LU0889565916.HKD","LU0823416689.USD","LU1201861249.SGD","LU1941712264.USD","LU0265550359.USD","IE0002141913.USD","SG9999014575.USD","IE00BJT1NW94.SGD","LU1989772840.SGD","LU0320765992.SGD","IE00BN8TJ469.HKD","LU0868494708.USD","LU1934455194.USD","SG9999015978.USD","LU0320765646.SGD","LU0122379950.USD","LU0058720904.USD","BK4568","BK4559","LU2089984988.USD","SG9999015945.SGD","SG9999001176.USD","BK4585","LU0106261372.USD","IE00B3T34201.USD","LU2125909247.SGD","LU1585245621.USD","LU1116320737.USD","LU2491049909.HKD","LU0234572021.USD","LU2491050154.USD","LU0130102774.USD","BK4139","LU0985320562.USD","LU0965509101.SGD","IE0009355771.USD","LU2491050071.SGD","LU1066053197.SGD","LU2361044865.SGD","LU2461242641.AUD","LU2106854487.HKD","LU0211331839.USD","LU1674673428.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU0477156953.USD","LU1066051225.USD","LU1917777945.USD","LU0203347892.USD","LU0130517989.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1066051811.HKD","IE00BLSP4239.USD","LU1093756325.SGD","IE00B4R5TH58.HKD","LU1974910355.USD","LU1035773651.USD","IE000M9KFDE8.USD","LU0965509283.SGD","LU2125154778.USD","LU0109394709.USD","LU0266013472.USD","LU2125154935.USD","LU0203345920.USD","LU0432979614.USD","IE00BBT3K403.USD","LU0234570918.USD","LU0265550946.USD","LU1116320901.HKD","SG9999001176.SGD","LU1037948897.HKD","SG9999015358.SGD","SGXZ57979304.SGD","LU1989771016.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU1061106388.HKD","LU0859254822.USD","BK4007","IE00B1BXHZ80.USD","BK4583","IE00BSNM7G36.USD","SG9999002224.SGD","LU0965508806.USD","BK4532","SG9999013999.USD","LU0980610538.SGD","SG9999015341.SGD","LU1778281490.HKD","LU1699723380.USD","BK4578","LU0320765489.SGD","IE00B2B36J28.USD","LU0238689110.USD","IE0002270589.USD","LU0006306889.USD","SG9999001440.SGD","LU1929549753.HKD","LU2468319806.SGD","LU1037948541.HKD","GILD","LU2112291526.USD","LU2360032135.SGD","IE00BZ1G4Q59.USD","BK4588","IE00BJJMRZ35.SGD","LU1923622614.USD","SG9999014542.SGD","BK4566","LU1989772923.USD","LU2361045086.USD","LU2087621335.USD","MRK","LU0648001328.SGD","LU1057294990.SGD","LU1674673691.USD","SG9999015952.SGD","LU0861579265.USD","LU0942090050.USD","LU1162221912.USD","LU1069347547.HKD","LU2023250504.SGD","LU0289739699.SGD","LU1934455277.USD","LU0070302665.USD","LU0965509010.AUD","LU1066051498.USD","LU2433249047.HKD","LU1934455863.HKD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171410707","title":"吉利德科学宣布两项评估口服每周一次HIV疗法Islatravir与Lenacapavir的三期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1171410707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171410707?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951057,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，其针对口服、每周一次给药的HIV治疗药物Islatravir与Lenacapavir的两项三期临床研究，均获得了积极的顶线结果。这一进展标志着该创新型长效治疗方案在关键性试验阶段迈出了重要一步，有望为HIV感染者的治疗管理带来新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","BK4588","GILD","LU2324357040.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","SG9999015952.SGD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1934455194.USD","SG9999015945.SGD","BK4585","BK4139","LU1571399168.USD","LU0320765992.SGD","LU1057294990.SGD","LU1430594728.SGD","BK4566","SG9999015978.USD","LU1674673428.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU1839511570.USD","LU0109394709.USD","LU1778281490.HKD","LU1934455277.USD","BK4578","LU0234570918.USD","BK4532","LU0965509101.SGD","BK4583","IE00B19Z3B42.SGD","BK4550","LU0882574055.USD","LU1037948897.HKD","LU1061106388.HKD","SG9999015986.USD","LU0861579265.USD","LU2087621335.USD","IE00B19Z3581.USD","LU0965508806.USD","LU0965509010.AUD","LU1023059063.AUD","LU2468319806.SGD","LU0823416689.USD","LU1066053197.SGD","LU0289739699.SGD","BK4568","LU2089984988.USD","IE0002270589.USD","LU1037948541.HKD","LU1934455863.HKD","LU0965509283.SGD","LU0122379950.USD","LU0058720904.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145372846","title":"吉利德与默克计划就伊斯拉曲韦/来那卡帕韦三期试验数据向全球监管机构提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1145372846","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145372846?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951047,"startTime":"0","endTime":"0","summary":"吉利德科学与其合作伙伴默克集团计划，将伊斯拉曲韦与来那卡帕韦联合用药的三期临床试验数据，提交给全球范围内的监管机构进行审评。此举标志着该候选药物在研发进程中迈出了关键一步，为其未来可能获批上市奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","IE00B7SZLL34.SGD","LU1934455194.USD","BK4583","LU0861579265.USD","IE00B3T34201.USD","IE00B19Z3581.USD","BK4585","LU1066051498.USD","LU1934455277.USD","LU0109394709.USD","BK4532","LU0058720904.USD","LU2087621335.USD","BK4588","LU0289739699.SGD","LU2089984988.USD","LU2468319806.SGD","GILD","BK4578","LU1061106388.HKD","SG9999015978.USD","LU0965509283.SGD","LU1057294990.SGD","LU0965509101.SGD","LU1066053197.SGD","LU1023059063.AUD","LU0823416689.USD","LU1778281490.HKD","MKGAF","BK4139","LU1934455863.HKD","LU1037948541.HKD","LU0889565916.HKD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","LU1674673691.USD","IE00B19Z3B42.SGD","BK4550","IE0002270589.USD","LU0882574055.USD","LU0114720955.EUR","SG9999015952.SGD","LU2324357040.USD","LU1839511570.USD","LU1430594728.SGD","SG9999015986.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU1037948897.HKD","LU1571399168.USD","LU0234570918.USD","LU0965508806.USD","BK4007","LU0965509010.AUD","SG9999015945.SGD","IE00BSNM7G36.USD","BK4566","BK4568","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164602486","title":"吉利德科学：Trodelvy与Keytruda联用的安全性特征与各药物已知安全性一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164602486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164602486?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:32","pubTimestamp":1780950760,"startTime":"0","endTime":"0","summary":"吉利德科学公司公布的数据显示，其抗体偶联药物Trodelvy与默沙东公司的Keytruda联合使用的安全性特征，与两种药物各自已知的安全性情况保持一致。这一发现为评估该联合疗法的潜力提供了重要的安全性基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","SG9999015952.SGD","LU1061106388.HKD","LU1934455277.USD","LU2357627491.SGD","LU0980610538.SGD","IE00B2B36J28.USD","SG9999015986.USD","SG9999001176.USD","LU2491050154.USD","LU1162221912.USD","LU2125909247.SGD","LU2023250504.SGD","SG9999014542.SGD","LU0320765646.SGD","LU0882574055.USD","LU1674673428.USD","LU0965508806.USD","LU2125909593.SGD","GILD","LU0648001328.SGD","BK4550","BK4588","SG9999015978.USD","BK4007","LU1037948897.HKD","LU2112291526.USD","IE00BKVL7J92.USD","LU0265550946.USD","IE00B3T34201.USD","LU1989772840.SGD","SG9999015358.SGD","LU0868494617.USD","LU1035773651.USD","SG9999002224.SGD","LU2106854487.HKD","BK4139","LU0070302665.USD","LU0477156953.USD","LU0320765489.SGD","IE00BZ1G4Q59.USD","LU2361044949.HKD","SG9999013999.USD","LU0265550359.USD","LU2433249047.HKD","LU1585245621.USD","LU0432979614.USD","LU1116320737.USD","LU1989772923.USD","LU0823416689.USD","SGXZ57979304.SGD","LU2491049909.HKD","LU0985320562.USD","LU1201861249.SGD","LU1974910355.USD","SG9999001440.SGD","LU1430594728.SGD","LU1989771016.USD","LU1066053197.SGD","LU1839511570.USD","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU2324357040.USD","IE00B19Z3581.USD","LU2125154935.USD","LU1066051811.HKD","SG9999015341.SGD","LU1674673691.USD","LU1934455194.USD","LU1093756168.USD","BK4534","BK4585","LU0320765992.SGD","LU2089984988.USD","LU1571399168.USD","LU2491050071.SGD","LU0238689110.USD","LU2361044865.SGD","BK4533","LU0208291251.USD","LU0289739699.SGD","LU1057294990.SGD","LU1923622614.USD","IE00B1BXHZ80.USD","LU2361045086.USD","LU2125154778.USD","BK4532","LU1983299246.USD","LU0098860793.USD","BK4568","LU2360032135.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0965509010.AUD","LU1917777945.USD","LU1699723380.USD","SG9999001176.SGD","IE00BLSP4452.SGD","LU0942090050.USD","LU0211331839.USD","LU1929549753.HKD","LU1116320901.HKD","LU0889565916.HKD","LU1023059063.AUD","MRK","IE00BBT3K403.USD","LU1037948541.HKD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0130517989.USD","LU0203345920.USD","BK4559","LU0106261372.USD","LU1066051225.USD","LU2023250843.SGD","SG9999015945.SGD","IE0009355771.USD","IE00BSNM7G36.USD","SG9999014575.USD","LU1941712348.USD","LU0266013472.USD","LU0058720904.USD","IE00BLSP4239.USD","LU1778281490.HKD","LU1934455863.HKD","LU0965509283.SGD","LU1093756325.SGD","IE000M9KFDE8.USD","SG9999014559.SGD","LU0859254822.USD","BK4566","LU0234570918.USD","BK4578","LU1069347547.HKD","LU1941712264.USD","LU0006306889.USD","LU0130102774.USD","LU0965509101.SGD","SG9999014567.USD","IE00BN8TJ469.HKD","LU2461242641.AUD","LU2087621335.USD","LU2468319806.SGD","LU0868494708.USD","LU1066051498.USD","LU1291159041.SGD","LU0861579265.USD","IE00B4R5TH58.HKD","LU0203347892.USD","BK4516","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU0234572021.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197062628","title":"吉利德科学宣布终止Trodelvy联合Keytruda的III期Keynote-D46/Evoke-03研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1197062628","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197062628?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:31","pubTimestamp":1780950708,"startTime":"0","endTime":"0","summary":"吉利德科学已决定终止其III期临床试验Keynote-D46/Evoke-03。该研究旨在评估其药物Trodelvy与默沙东的Keytruda联合用药方案。\n此项研究的终止意味着该联合疗法的开发进程已告一段落。吉利德科学未在本次公告中披露终止该研究的详细原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550359.USD","LU1983299246.USD","SG9999014567.USD","LU2106854487.HKD","SG9999013999.USD","BK4568","IE00B2B36J28.USD","LU2491050154.USD","IE00BBT3K403.USD","LU1934455194.USD","LU2089984988.USD","SGXZ57979304.SGD","SG9999015978.USD","LU1069347547.HKD","LU1934455277.USD","IE00B7SZLL34.SGD","LU1917777945.USD","LU0965509010.AUD","LU1201861249.SGD","LU0980610538.SGD","LU0122379950.USD","LU0234572021.USD","LU0477156953.USD","SG9999002232.USD","BK4533","LU1571399168.USD","LU1162221912.USD","IE00BJT1NW94.SGD","SG9999015945.SGD","LU2125154778.USD","LU1585245621.USD","LU1061106388.HKD","LU0203345920.USD","SG9999015952.SGD","LU1674673428.USD","BK4534","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU0098860793.USD","LU1066053197.SGD","LU1974910355.USD","LU1989772840.SGD","LU0985320562.USD","LU2361044865.SGD","SG9999014542.SGD","LU1934455863.HKD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU0058720904.USD","LU2361044949.HKD","LU0965509283.SGD","LU1037948897.HKD","LU0965509101.SGD","LU0203347892.USD","IE00B3T34201.USD","LU1778281490.HKD","LU0266013472.USD","LU0889565916.HKD","LU0106261372.USD","LU2360032135.SGD","SG9999001440.SGD","BK4007","IE00BZ1G4Q59.USD","LU1699723380.USD","LU2468319806.SGD","LU1116320737.USD","LU0130102774.USD","LU0234570918.USD","SG9999015986.USD","LU0859254822.USD","BK4550","GILD","MRK","SG9999015358.SGD","IE00B19Z3581.USD","IE00BN8TJ469.HKD","LU2361045086.USD","LU0070302665.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU0265550946.USD","LU2087621335.USD","LU2433249047.HKD","LU0320765489.SGD","LU2461242641.AUD","LU1674673691.USD","LU2491049909.HKD","LU0861579265.USD","SG9999002224.SGD","BK4583","LU0289739699.SGD","LU2491050071.SGD","LU0432979614.USD","LU0208291251.USD","LU1066051498.USD","LU1093756325.SGD","LU1989771016.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU0868494708.USD","LU2125154935.USD","LU0320765992.SGD","IE00BLSP4239.USD","LU0109394709.USD","IE00BLSP4452.SGD","SG9999014559.SGD","BK4578","LU0320765646.SGD","LU1093756168.USD","BK4585","LU2125909593.SGD","LU1941712348.USD","LU1037948541.HKD","BK4566","LU1057294990.SGD","LU2125909247.SGD","SG9999015341.SGD","LU1116320901.HKD","LU1291159041.SGD","LU2023250504.SGD","LU0823416689.USD","BK4516","SG9999001176.SGD","IE0002141913.USD","BK4559","LU1839511570.USD","LU1989772923.USD","LU0648001328.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4139","SG9999014575.USD","LU2112291526.USD","LU0006306889.USD","LU1941712264.USD","LU2357627491.SGD","LU0238689110.USD","LU2023250843.SGD","LU0965508806.USD","LU1923622614.USD","LU2324357040.USD","LU0130517989.USD","LU1066051225.USD","IE000M9KFDE8.USD","IE00BSNM7G36.USD","LU1035773651.USD","LU1066051811.HKD","BK4532","IE00B1BXHZ80.USD","SG9999001176.USD","IE0002270589.USD","LU0942090050.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154475153","title":"吉利德科学公布52周数据：ALP正常化率持续高位，安全性总体耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1154475153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154475153?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:35","pubTimestamp":1780403750,"startTime":"0","endTime":"0","summary":"吉利德科学最新发布的52周临床研究结果显示，其疗法展现出高且持续的血清碱性磷酸酶（ALP）正常化率。同时，该疗法的安全性特征总体良好，耐受性高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0289739699.SGD","LU1023059063.AUD","LU1934455277.USD","LU0965509010.AUD","SG9999015986.USD","LU2112291526.USD","LU1934455194.USD","GILD","LU1839511570.USD","LU1066053197.SGD","LU0882574055.USD","LU0823416689.USD","LU0234570918.USD","IE0002270589.USD","LU0058720904.USD","LU0965508806.USD","LU1061106388.HKD","LU1778281490.HKD","IE00B3T34201.USD","LU1037948897.HKD","LU0861579265.USD","LU1934455863.HKD","LU1037948541.HKD","LU1674673691.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1057294990.SGD","LU2468319806.SGD","BK4566","IE00BKVL7J92.USD","LU0965509101.SGD","BK4585","LU2324357040.USD","IE00BSNM7G36.USD","LU1571399168.USD","BK4139","BK4583","SG9999015945.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0114720955.EUR","IE00B19Z3581.USD","BK4550","LU0889565916.HKD","BK4588","LU1585245621.USD","LU1674673428.USD","SG9999015978.USD","BK4568","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU0122379950.USD","LU0320765992.SGD","LU1066051498.USD","LU2089984988.USD","BK4532","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155362957","title":"吉利德科学旗下Livdelzi® (Seladelpar) 在原发性胆汁性胆管炎(PBC) III期IDEAL试验中实现具有统计学意义的复合ALP正常化","url":"https://stock-news.laohu8.com/highlight/detail?id=1155362957","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155362957?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:30","pubTimestamp":1780403420,"startTime":"0","endTime":"0","summary":"吉利德科学公司研发的Livdelzi® (Seladelpar) 在针对原发性胆汁性胆管炎（PBC）的III期IDEAL临床试验中，取得了具有统计学意义的复合碱性磷酸酶（ALP）正常化结果。该积极数据标志着这款在研药物在治疗这一慢性肝病方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU0965509010.AUD","LU1037948541.HKD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0965508806.USD","IE00B19Z3B42.SGD","LU1066051498.USD","LU1778281490.HKD","SG9999015986.USD","IE00B3T34201.USD","LU1571399168.USD","LU2089984988.USD","LU1061106388.HKD","BK4568","LU1585245621.USD","BK4578","IE00BSNM7G36.USD","LU0289739699.SGD","LU1057294990.SGD","IE00B19Z3581.USD","LU0109394709.USD","LU0320765992.SGD","BK4566","LU2324357040.USD","SG9999015978.USD","BK4139","BK4583","BK4585","IE00B7SZLL34.SGD","SG9999015945.SGD","LU1066053197.SGD","BK4532","LU0823416689.USD","LU0965509101.SGD","LU0965509283.SGD","IE0002270589.USD","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","BK4550","LU1934455194.USD","LU0234570918.USD","LU0861579265.USD","IE00BKVL7J92.USD","LU1023059063.AUD","LU1037948897.HKD","LU0114720955.EUR","SG9999015952.SGD","LU2087621335.USD","LU1674673428.USD","LU1839511570.USD","LU0889565916.HKD","BK4588","LU1430594728.SGD","GILD","LU1674673691.USD","LU2112291526.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064750","title":"Cencora与Kite达成协议，支持其FDA批准的CAR-T细胞疗法Yescarta与Tecartus在美国的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064750","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146064750?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:06","pubTimestamp":1780401987,"startTime":"0","endTime":"0","summary":"Cencora Inc.宣布与吉利德科学旗下公司Kite达成一项协议，将支持Kite旗下两款已获美国食品药品监督管理局批准的CAR-T细胞疗法——Yescarta与Tecartus——在美国市场的分销工作。该合作旨在强化这些创新癌症疗法的供应链与可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1814569148.SGD","SG9999015952.SGD","LU1061106388.HKD","LU1430594728.SGD","LU0965509283.SGD","LU1084165304.USD","BK4532","LU1261432733.SGD","LU1839511570.USD","LU0320765992.SGD","LU1057294990.SGD","LU0289739699.SGD","LU1934455277.USD","BK4583","LU0965509010.AUD","LU1023059063.AUD","LU1037948897.HKD","LU1585245621.USD","LU1674673691.USD","LU2237957902.USD","LU2324357040.USD","BK4550","IE0002270589.USD","LU2112291526.USD","LU0965509101.SGD","LU0823416689.USD","IE00B3T34201.USD","BK4588","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU1119994496.HKD","LU1778281490.HKD","BK4175","LU1934455863.HKD","LU1066053197.SGD","LU0965508806.USD","SGXZ23171101.USD","LU0114720955.EUR","BK4578","LU0122379950.USD","SG9999015945.SGD","LU0861579265.USD","COR","IE00B7SZLL34.SGD","BK4084","LU1571399168.USD","LU2237957811.SGD","BK4585","LU0058720904.USD","LU1674673428.USD","LU0882574055.USD","LU1037948541.HKD","LU2087621335.USD","BK4568","LU2468319806.SGD","SG9999015978.USD","BK4139","LU0234570918.USD","LU1934455194.USD","IE00BZ1G4Q59.USD","BK4566","IE00BSNM7G36.USD","SG9999004303.SGD","SG9999015986.USD","LU1066051498.USD","GILD","IE00BKVL7J92.USD","LU2089984988.USD","BK4529","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184286246","title":"异动解读｜吉利德科学盘中上涨3.04%，核心药物Trodelvy获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1184286246","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184286246?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:59","pubTimestamp":1779479951,"startTime":"0","endTime":"0","summary":"5月22日，吉利德科学盘中上涨3.04%，报134.47美元/股，成交额5.59亿美元。消息面上，吉利德科学宣布其抗体药物偶联物Trodelvy获得欧洲药品管理局人用药品委员会积极意见，支持批准其作为一线转移性三阴性乳腺癌疗法，用于不适合PD-1抑制剂治疗的患者。III期临床数据显示，Trodelvy较传统化疗将疾病进展或死亡风险降低38%，欧盟委员会最终决定预计年内作出。此外，公司已完成对德国Tubulis的31.5亿美元收购，进一步强化ADC布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129505357","title":"FDA批准Hepcludex注射剂用于治疗无肝硬化或代偿期肝硬化成人慢性丁型肝炎病毒感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1129505357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129505357?lang=zh_cn&edition=full","pubTime":"2026-05-23 01:38","pubTimestamp":1779471495,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Hepcludex注射剂，用于治疗未伴有肝硬化或处于代偿期肝硬化的成人慢性丁型肝炎病毒（HDV）感染。这一决定为患有这种严重肝脏疾病的患者群体提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1839511570.USD","BK4588","BK4578","LU1674673691.USD","BK4568","BK4550","LU1057294990.SGD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU1778281490.HKD","BK4566","LU0889565916.HKD","BK4139","LU2112291526.USD","SG9999015978.USD","BK4585","LU0965509101.SGD","LU0965509283.SGD","LU0122379950.USD","LU1934455277.USD","IE00B3T34201.USD","LU0965509010.AUD","GILD","IE00BSNM7G36.USD","LU1066053197.SGD","SG9999015986.USD","LU1066051498.USD","IE00B7SZLL34.SGD","LU1571399168.USD","LU0882574055.USD","LU1037948541.HKD","LU1061106388.HKD","LU2089984988.USD","LU1934455863.HKD","SG9999015945.SGD","SG9999015952.SGD","IE00B19Z3581.USD","LU0320765992.SGD","LU1674673428.USD","LU0114720955.EUR","LU2324357040.USD","BK4532","LU1430594728.SGD","LU0861579265.USD","LU0289739699.SGD","LU0109394709.USD","IE00BKVL7J92.USD","LU0234570918.USD","LU0058720904.USD","LU1934455194.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4583","LU0823416689.USD","LU1037948897.HKD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189035839","title":"吉利德科学Trodelvy®获欧盟CHMP积极意见，用于不适合PD-(L)1抑制剂患者的一线转移性三阴性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1189035839","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189035839?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:49","pubTimestamp":1779450575,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，其药物Trodelvy获得了欧洲药品管理局人用药品委员会的积极意见。该意见支持批准Trodelvy用于治疗不适合接受PD-1抑制剂的患者群体，作为一线转移性三阴性乳腺癌的疗法。这一积极意见是基于关键的III期临床试验数据。研究结果表明，与医生选择的化疗相比，Trodelvy在无进展生存期和总生存期方面均显示出具有统计学意义和临床意义的改善。欧盟委员会在审查药品上市许可申请时，通常会采纳CHMP的意见，最终决定预计将在未来几个月内做出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4583","LU1066051498.USD","LU1585245621.USD","LU0965509283.SGD","LU0109394709.USD","LU1674673428.USD","LU2089984988.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","BK4566","BK4532","LU1934455277.USD","LU2087621335.USD","LU1674673691.USD","IE00BSNM7G36.USD","BK4139","SG9999015952.SGD","BK4578","SG9999015945.SGD","IE00B19Z3581.USD","LU1571399168.USD","LU0861579265.USD","LU0965509101.SGD","LU1037948897.HKD","LU0234570918.USD","LU1061106388.HKD","LU1934455194.USD","LU0882574055.USD","LU0122379950.USD","LU1023059063.AUD","SG9999015978.USD","LU0965508806.USD","LU1037948541.HKD","GILD","BK4568","BK4588","IE00BKVL7J92.USD","LU1778281490.HKD","IE00B3T34201.USD","LU0823416689.USD","LU1934455863.HKD","IE00B7SZLL34.SGD","SG9999015986.USD","IE0002270589.USD","LU0320765992.SGD","BK4585","LU2468319806.SGD","BK4550","LU0965509010.AUD","LU1057294990.SGD","LU0289739699.SGD","LU1839511570.USD","LU2112291526.USD","LU0058720904.USD","LU0889565916.HKD","LU1430594728.SGD","LU2324357040.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129804946","title":"2026年ASCO与EHA新数据揭示吉利德科学及Kite在抗体药物偶联物与细胞疗法领域的强劲势头","url":"https://stock-news.laohu8.com/highlight/detail?id=1129804946","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129804946?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:01","pubTimestamp":1779397275,"startTime":"0","endTime":"0","summary":"2026年美国临床肿瘤学会（ASCO）与欧洲血液学协会（EHA）年会发布的最新数据，有力彰显了吉利德科学及其旗下Kite公司在肿瘤治疗领域，特别是在抗体药物偶联物（ADC）与细胞疗法两大前沿方向上的显著进展与持续动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","LU0889565916.HKD","LU1037948541.HKD","LU2089984988.USD","BK4588","LU1061106388.HKD","BK4532","LU2112291526.USD","BK4566","LU1839511570.USD","LU0109394709.USD","IE00B19Z3581.USD","BK4139","LU1571399168.USD","LU1934455863.HKD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU1934455277.USD","LU2468319806.SGD","LU0114720955.EUR","LU0320765992.SGD","SG9999015978.USD","IE0002270589.USD","SG9999015986.USD","BK4550","LU1066051498.USD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","LU1934455194.USD","LU0823416689.USD","LU0965509010.AUD","LU0965509101.SGD","LU0965509283.SGD","BK4583","BK4585","GILD","SG9999015952.SGD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0861579265.USD","LU1066053197.SGD","LU1674673428.USD","LU1037948897.HKD","IE00B19Z3B42.SGD","SG9999015945.SGD","BK4568","LU0058720904.USD","LU1023059063.AUD","LU0882574055.USD","LU1430594728.SGD","LU1674673691.USD","IE00B3T34201.USD","LU0122379950.USD","BK4578","LU0234570918.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181163516","title":"吉利德科学与世卫组织深化合作，致力消除致命寄生虫病内脏利什曼病","url":"https://stock-news.laohu8.com/highlight/detail?id=1181163516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181163516?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:31","pubTimestamp":1779348675,"startTime":"0","endTime":"0","summary":"吉利德科学与世界卫生组织宣布扩大合作范围，共同致力于在全球范围内消除一种致命性的寄生虫疾病——内脏利什曼病。此项合作旨在整合双方的专业知识与资源，加速推进疾病防控策略的实施，以减轻该疾病对公共卫生造成的沉重负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4583","LU1066051498.USD","LU1585245621.USD","LU0965509283.SGD","LU0109394709.USD","LU1674673428.USD","LU2089984988.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","BK4566","BK4532","LU1934455277.USD","LU2087621335.USD","LU1674673691.USD","IE00BSNM7G36.USD","BK4139","SG9999015952.SGD","BK4578","SG9999015945.SGD","IE00B19Z3581.USD","LU1571399168.USD","LU0861579265.USD","LU0965509101.SGD","LU1037948897.HKD","LU0234570918.USD","LU1061106388.HKD","LU1934455194.USD","LU0882574055.USD","LU0122379950.USD","LU1023059063.AUD","SG9999015978.USD","LU0965508806.USD","LU1037948541.HKD","GILD","BK4568","BK4588","IE00BKVL7J92.USD","LU1778281490.HKD","IE00B3T34201.USD","LU0823416689.USD","LU1934455863.HKD","IE00B7SZLL34.SGD","SG9999015986.USD","IE0002270589.USD","LU0320765992.SGD","BK4585","LU2468319806.SGD","BK4550","LU0965509010.AUD","LU1057294990.SGD","LU0289739699.SGD","LU1839511570.USD","LU2112291526.USD","LU0058720904.USD","LU0889565916.HKD","LU1430594728.SGD","LU2324357040.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153011017","title":"吉利德科学：因预期115亿美元收购IPR&D费用及交易相关融资成本，更新后全年每股收益及调整后每股收益指引下调约9.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153011017","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153011017?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:02","pubTimestamp":1778184133,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，由于预期将产生高达115亿美元的收购IPR&D（已获授权研发资产）费用，以及相关交易产生的融资成本，公司决定大幅下调其全年每股收益及调整后每股收益的财务指引，下调幅度约为9.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU1066053197.SGD","SG9999015952.SGD","BK4568","LU1674673691.USD","GILD","IE00B19Z3B42.SGD","LU0861579265.USD","SG9999015978.USD","BK4532","IE0002270589.USD","LU1934455277.USD","LU0320765992.SGD","LU1934455863.HKD","LU0234570918.USD","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU0965509283.SGD","IE00B19Z3581.USD","LU2089984988.USD","SG9999015945.SGD","LU1839511570.USD","LU1066051498.USD","BK4139","LU1037948897.HKD","LU0109394709.USD","LU1571399168.USD","BK4550","LU2468319806.SGD","LU0965508806.USD","LU1934455194.USD","LU1023059063.AUD","BK4566","LU0882574055.USD","LU1061106388.HKD","LU1585245621.USD","LU2112291526.USD","LU0889565916.HKD","LU1430594728.SGD","LU1778281490.HKD","LU2324357040.USD","IE00BSNM7G36.USD","BK4578","SG9999015986.USD","LU1037948541.HKD","LU2087621335.USD","IE00B3T34201.USD","LU0289739699.SGD","LU0122379950.USD","BK4588","BK4585","LU0058720904.USD","IE00B7SZLL34.SGD","LU1674673428.USD","IE00BKVL7J92.USD","LU0114720955.EUR","LU0823416689.USD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113663015","title":"财报前瞻｜吉利德科学本季度营收预计增1.57%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1113663015","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113663015?lang=zh_cn&edition=full","pubTime":"2026-04-30 13:22","pubTimestamp":1777526524,"startTime":"0","endTime":"0","summary":"吉利德科学预计于20260507盘后发布财报，市场聚焦收入韧性与在研资产推进对盈利结构的边际影响。市场一致预期显示，本季度吉利德科学营收预计为69.13亿美元，同比增加1.57%；调整后每股收益预计为1.91美元，同比增加7.24%；息税前利润预计为31.21亿美元，同比增加10.10%。上季度吉利德科学营收79.25亿美元，同比增长4.70%；毛利率79.56%；归母净利润21.83亿美元，净利率27.55%；调整后每股收益1.86美元，同比下降2.11%。在本次收集的机构观点中，看多意见占比较高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜吉利德科学本季度营收预计增1.57%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":-0.0561},{"period":"3month","weight":-0.1338},{"period":"6month","weight":0.0431},{"period":"1year","weight":0.1208},{"period":"ytd","weight":0.0232}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.628571,"avgChangeRate":0.02306},{"month":7,"riseRate":0.558824,"avgChangeRate":0.01609},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}